BioLine RX Book Value Per Share vs. Cash Flow From Operations
| BLRX Stock | ILS 7.70 0.40 4.94% |
For BioLine RX profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLine RX to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLine RX utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLine RX's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLine RX over time as well as its relative position and ranking within its peers.
BioLine |
BioLine RX Cash Flow From Operations vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioLine RX's current stock value. Our valuation model uses many indicators to compare BioLine RX value to that of its competitors to determine the firm's financial worth. BioLine RX is number one stock in book value per share category among its peers. It also is number one stock in cash flow from operations category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLine RX by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLine RX's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BioLine Cash Flow From Operations vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
BioLine RX |
| = | 0.08 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
BioLine RX |
| = | (23.57 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
BioLine Cash Flow From Operations Comparison
BioLine RX is currently under evaluation in cash flow from operations category among its peers.
BioLine RX Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioLine RX, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLine RX will eventually generate negative long term returns. The profitability progress is the general direction of BioLine RX's change in net profit over the period of time. It can combine multiple indicators of BioLine RX, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
BioLine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioLine RX. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLine RX position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLine RX's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in BioLine RX without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Use Investing Themes to Complement your BioLine RX position
In addition to having BioLine RX in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Candy and Soda Thematic Idea Now
Candy and Soda
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Candy and Soda theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Candy and Soda Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BioLine Stock
To fully project BioLine RX's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioLine RX at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioLine RX's income statement, its balance sheet, and the statement of cash flows.